Improving Heart Health in Appalachia

NCT ID: NCT01884246

Last Updated: 2017-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-01

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Individuals in Appalachian Kentucky are vulnerable to cardiovascular disease (CVD) by virtue of having high rates of multiple CVD risk factors. There is a critical need to develop and test CVD risk reducing interventions that are appropriate and effective in Appalachia. In the absence of such interventions, the dramatic CVD disparities seen in this area will continue to rise.

Lifestyle interventions reduce CVD risk by 44%. The investigators and others have demonstrated that lifestyle change is most effective when patients are given the tools to engage in effective self-care, and that interventions individualized to patients' specific needs and barriers are more effective than interventions that are not. The central hypothesis is that to be successful in Appalachia, CVD risk reducing interventions must focus on patient-centered lifestyle change that increase individuals' abilities to engage in self-care, must be culturally appropriate, and must have components that overcome barriers faced by individuals living in Appalachia.

The investigators propose a randomized, controlled comparative effectiveness trial with 300 individuals from Appalachian Kentucky who do not have a primary care provider and who are at risk for CVD by virtue of having two or more modifiable CVD risk factors. The investigators will compare (1) a patient-centered, culturally appropriate, self-care CVD risk reduction intervention (HeartHealth) designed to improve multiple CVD risk factors while overcoming barriers to success with (2) referral of patients to a primary care provider for management of their CVD risk factors. The investigators propose the following specific aims to be tested at 4 months and 1 year after baseline. To compare the short and long-term impact of the interventions on:

1\) the risk factor selected by patients (i.e., tobacco use, blood pressure, lipid profile, hemoglobin-A1c (HgA1c) for diabetics, body mass index, waist circumference, depressive symptoms, or physical activity level); 2) all of the CVD risk factors of each patient; 3) quality of life; 4) patient and healthcare provider satisfaction; 5) desirability and adoptability by assessing adherence to recommended CVD risk reduction measures, and retention of recruited individuals. The investigators hypothesize that in comparison to the referral strategy, the multifaceted patient-centered, self-care intervention will engender more favorable outcomes across all measures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Hypertension Hyperlipidemia Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Self-care CVD risk reduction

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Group Type EXPERIMENTAL

Self-care CVD risk reduction

Intervention Type BEHAVIORAL

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Referral to primary care provider for CVD risk management

Intervention Type OTHER

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Referral to primary care provider

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Group Type ACTIVE_COMPARATOR

Referral to primary care provider for CVD risk management

Intervention Type OTHER

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Self-care CVD risk reduction

A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Intervention Type BEHAVIORAL

Referral to primary care provider for CVD risk management

The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HeartHealth

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* residents of eastern Appalachian Kentucky
* do not have a primary care provider
* at risk for CVD as reflected by having two or more of the following modifiable risk factors

1. clinical diagnosis of hypertension or taking medications diagnosed for hypertension or found to be hypertensive on screening;
2. clinical diagnosis of hyperlipidemia or taking medication for treating abnormal lipid levels, or any lipid abnormality found on screening that indicates hyperlipidemia;
3. diagnosis of type 2 diabetes or HgA1c \> 7% found on screening;
4. overweight or obese (body mass index ≥ 25 kg/m2);
5. waist circumference \> 40 inches in men or \> 35 inches in women;
6. clinical diagnosis of depression, on medications for depression or found to have depressive symptoms (score of \> 9 on the Patient Health Questionnaire-9) by baseline screening;
7. sedentary lifestyle meaning that the individual does not engage in at least 30 minutes of moderate activity for at least 4 days per week

Exclusion Criteria

* known coronary artery disease, cerebrovascular disease, history of acute coronary syndrome or peripheral arterial disease;
* taking medications (e.g., protease inhibitors) that interfere with lipid metabolism;
* cognitive impairment that precludes an individual from understanding the consent process, answering questionnaires, or participating in the intervention;
* chronic drug abuse;
* end-stage renal or liver or pulmonary disease;
* current active cancer (i.e., undergoing active treatment for cancer) other than isolated skin cancer treatable by simple excision;
* gastrointestinal disease that requires special diets (e.g., Crohn's disease; celiac disease)
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Kentucky Center for Excellence in Rural Health-Hazard

UNKNOWN

Sponsor Role collaborator

Debra Moser

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Debra Moser

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Debra K Moser, DNSc, RN

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Kentucky

Lexington, Kentucky, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PCORI 3048110484

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CommunityRx-Cardiovascular Disease
NCT06264726 ACTIVE_NOT_RECRUITING NA